References
EMA. COVID-19 Vaccine AstraZeneca: benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets. Internet Document : 18 Mar 2021. Available from: URL: https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-benefits-still-outweigh-risks-despite-possible-link-rare-blood-clots.
WHO. Statement of the WHO Global Advisory Committee on Vaccine Safety (GACVS) COVID-19 subcommittee on safety signals related to the AstraZeneca COVID-19 vaccine. Internet Document : 19 Mar 2021. Available from: URL: https://www.who.int/news/item/19-03-2021-statement-of-the-who-global-advisory-committee-on-vaccine-safety-(gacvs)-covid-19-subcommittee-on-safety-signals-related-to-the-astrazeneca-covid-19-vaccine.
MHRA. UK regulator confirms that people should continue to receive the COVID-19 vaccine AstraZeneca. Internet Document : 18 Mar 2021. Available from: URL: https://www.gov.uk/government/news/uk-regulator-confirms-that-people-should-continue-to-receive-the-covid-19-vaccine-astrazeneca.
Rights and permissions
About this article
Cite this article
Benefits of COVID-19 Vaccine AstraZeneca outweigh risks of blood clots. Reactions Weekly 1848, 2 (2021). https://doi.org/10.1007/s40278-021-93004-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-021-93004-3